DNA probes are single-stranded DNA stretches used by hybridization to recognise the presence of complementary nucleic acid sequences (target sequences). They allow researchers to detect a distinct sequence of DNA in a mixture, marked with a label like colour or fluorescence. First, to differentiate the DNA strands after which the probe is applied, the DNA sample is heated.
The increasing adoption of DNA probes in new disease identification has resulted in new players being invested and forayed. Fact.MR, a global research and consulting firm, analyses the market for diagnostics based on DNA probes in detail in its new report, providing comprehensive coverage of the key success factors.
Increasing public awareness of this prenatal diagnostic and carrier detection technology is increasing rapidly and is expected to result in a substantial increase in demand for such services in the coming years. In addition, the increasing penetration of automation in diagnostic tests is projected to generate lucrative growth opportunities for the diagnostics market based on global DNA probes. The DNA-probes-based diagnostics market is likely to grow by more than 5% during the period 2020-2030.
Diagnostics based on DNA probes examine the undoing of an anomalous sequence of genes present in the DNA strand. This technology is used in the development of instrumentation, surface chemistry, molecular biology, handling of data, preparation of biological samples and microfabrication. Increasing awareness of DNA probes based diagnostics for prenatal diagnosis and carrier detection is expected to drive demand.
The use of DNA probe-based diagnostics in the diagnosis of bacterial infections caused by Salmonella typhi (food poisoning), Escherichia coli (gastroenteritis), and Campylobacter hyointestinalis has increased the emergence of infectious diseases. It is expected that the introduction of new technologies for high volume testing will propel market growth, Fact.MR Analysis
- Global revenue to rise by 2030 at over 5 percent CAGR
- Introduction of in-situ hybridization with non-isotopic DNA probes to create opportunities for segment testing for infectious diseases
- The growing need for molecular diagnosis of diseases such as cancer remains a key opportunity.
- Limitations due to errors caused by recombination, incorrect pedigree data and genetic heterogeneity between the marker and illness alleles.
Industries all over the world have been disrupted by the COVID-19 pandemic, and the healthcare industry is no different. Nevertheless, due to the increased need for diagnostics during the pandemic, the market experienced demand. Following the advent of the COVID-19 pandemic, the market is likely to experience constant demand for DNA probe-based diagnostics.
In Situ Hybridization Market: IntroductionIn situ hybridization is a technique used to label complementary DNA, RNA, or modified nucleic acids strand.
The technique helps localize specific DNA or RNA sequence in the small cross-section of tissues or an entire tissue.
Hybridization technique is frequently employed for the location of specific nucleic acid sequences on chromosomes or in tissues to understand the organization, regulation, and function of gene.Request Brochure – https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=56169The In situ hybridization technique expands the capabilities to satisfy any therapy needs and enable a new diagnostic, treatment application for patients suffering from cancer or other chronic diseases.
Its unique technology in rapid detection of aneuploidies during prenatal stage ensure better functional ability to detect abnormalities related to birth defects or mental disorders.
This is likely to restrain the adoption of in situ hybridization technique in laboratories.Request COVID Analysis on In Situ Hybridization Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19_id=56169Key Drivers, Restraints, and Opportunities of Global In Situ Hybridization MarketCases of cancer have been rising globally for the last few years.
However, the lack of a commercial market for diagnostic procedures has resulted in the availability of a small number of diagnostic tests in emerging economies.
